biostudies-literatureAhlenstiel-Grunow TBundesministerium für Bildung und ForschungNovartis502-516https://www.ebi.ac.uk/biostudies/studies/S-EPMC8054884biostudies-literatureUnknown32(2)<h4>Background</h4>Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after transplantation. Virus-specific T cells correlate with both virus-specific and general cellular immune defense. Additional steering of immunosuppressive therapy by virus-specific T cell levels might optimize dosing of immunosuppressants.<h4>Methods</h4>In a multicenter, randomized, controlled trial, we randomized 64 pediatric kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an intervention group with additional steering of immunosuppressive therapy by levels of virus-specific T cells (quantified by cytokine flow cytometry). Both groups received immunosuppression with cyclosporin A and everolimus in the same target range of trough leJournal of the American Society of Nephrology : JASNSteering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial.PMC805488401EO0802Liu XGroßhennig AStaude HSabau ROh JSchild RTaylan CWeber LTPape LAhlenstiel-Grunow TVerboom MSchroder CfalseSteering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial.<h4>Background</h4>Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after transplantation. Virus-specific T cells correlate with both virus-specific and general cellular immune defense. Additional steering of immunosuppressive therapy by virus-specific T cell levels might optimize dosing of immunosuppressants.<h4>Methods</h4>In a multicenter, randomized, controlled trial, we randomized 64 pediatric kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an intervention group with additional steering of immunosuppressive therapy by levels of virus-specific T cells (quantified by cytokine flow cytometry). Both groups received immunosuppression with cyclosporin A and everolimus in the same target range of trough le2021-01-01T00:00:00Z2021 Feb2026-04-29T10:10:53.495Z2022-02-11T15:44:01.696ZS-EPMC80548843332347310.1681/asn.202005064510.1681/ASN.2020050645